BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

Bright Minds Biosciences (DRUG) added ~10% in the premarket on Tuesday after the company said that its lead asset, BMB-101, ...

The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline. ・In the Absence cohort, patients experienced a median 73.1% reduction in seizures. ・The DEE cohort saw a ...

Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...

(NewsNation) — March 26 is Purple Day, a day dedicated to raising awareness about epilepsy worldwide. An estimated 50 million people worldwide are diagnosed with epilepsy, and seizures are the main ...

Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...

Since 1983, eight new AEDs have been introduced (see Table 2 below). Sadly, a recent VA study of more than 21,000 subjects aged 65 years and older revealed that 80% were being treated with ...

CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cavion, Inc., a clinical stage biotechnology company developing novel therapeutics for neurological diseases, announced today that their first ...

Absence seizures, common in children, present as brief lapses in awareness, often mistaken for daydreaming. These non-convulsive seizures involve staring spells and subtle movements, potentially ...